Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ALS-linked loss of Cyclin-F function affects HSP90. | Life Sci Alliance | 2022 | 36114006 | PubTator, text mining | PubMed |
| Molecular architecture of the autoinhibited kinesin-1 lambda particle. | Sci Adv | 2022 | 36112680 | PubTator, text mining | PubMed |
| Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. | Cancer Sci | 2022 | 36106376 | PubTator, text mining | PubMed |
| Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report. | Transl Cancer Res | 2022 | 36093550 | PubTator, text mining | PubMed |
| Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. | Cancer Res | 2022 | 36074020 | PubTator, text mining | PubMed |
| Epigenetic profiling reveals a subset of pediatric-type glioneuronal tumors characterized by oncogenic gene fusions involving several targetable kinases. | Acta Neuropathol | 2022 | 36070143 | PubTator, text mining | PubMed |
| Structural model of microtubule dynamics inhibition by kinesin-4 from the crystal structure of KLP-12 -tubulin complex. | Elife | 2022 | 36065637 | PubTator, text mining | PubMed |
| Microtubule Dumbbells to Assess the Effect of Force Geometry on Single Kinesin Motors. | Methods Mol Biol | 2022 | 36063334 | PubTator, text mining | PubMed |
| RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer. | J Transl Med | 2022 | 36059009 | PubTator, text mining | PubMed |
| Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome. | Oncoimmunology | 2022 | 36046812 | PubTator, text mining | PubMed |
| A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report. | Open Life Sci | 2022 | 36045716 | PubTator, text mining | PubMed |
| Translating extracellular vesicle packaging into therapeutic applications. | Front Immunol | 2022 | 36045692 | PubTator, text mining | PubMed |
| Phosphorylation of FAM134C by CK2 controls starvation-induced ER-phagy. | Sci Adv | 2022 | 36044577 | PubTator, text mining | PubMed |
| Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing. | Front Oncol | 2022 | 36033527 | PubTator, text mining | PubMed |
| Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin. | Front Oncol | 2022 | 36033470 | PubTator, text mining | PubMed |
| A ribosomally synthesised and post-translationally modified peptide containing a β-enamino acid and a macrocyclic motif. | Nat Commun | 2022 | 36028509 | PubTator, text mining | PubMed |
| Human Papillomavirus 16 E6 and E7 Oncoproteins Alter the Abundance of Proteins Associated with DNA Damage Response, Immune Signaling and Epidermal Differentiation. | Viruses | 2022 | 36016386 | PubTator, text mining | PubMed |
| Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance. | Cancers (Basel) | 2022 | 36010871 | PubTator, text mining | PubMed |
| Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics. | Diagnostics (Basel) | 2022 | 36010306 | PubTator, text mining | PubMed |
| Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion. | Front Oncol | 2022 | 36003768 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=25